1.
Antithrombotic treatment in atrial fibrillation
by Lip, G Y H
Heart (British Cardiac Society), 2006-02, Vol.25 (2), p.1163-161
3.
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial
by Ng, Kuan H
Age and ageing, 2016-01, Vol.45 (1), p.77-83
4.
Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
by Lopes, Renato D
The American heart journal, 2017, Vol.189, p.137-145
5.
Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate...
by Kirchhof, Paulus
The American heart journal, 2017, Vol.190, p.12-18
6.
7.
Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analy...
by Caldeira, Daniel
Heart (British Cardiac Society), 2015-08, Vol.101 (15), p.1204-1211
8.
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
by Kotecha, Dipak, Dr
The Lancet (British edition), 2014, Vol.384 (9961), p.2235-2243
9.
Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation
by Sardu, Celestino
The American journal of cardiology, 2017-05-01, Vol.119 (9), p.1382-1386
10.
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
by Healey, Jeff S, Dr
The Lancet (British edition), 2016, Vol.388 (10050), p.1161-1169
11.
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis
by Providencia, Rui
Heart (British Cardiac Society), 2016-10-01, Vol.102 (19), p.1533-1543
12.
Atrial fibrillation is associated with different levels of physical activity levels at different ages in men
by Drca, Nikola
Heart (British Cardiac Society), 2014-07, Vol.100 (13), p.1037-1042
13.
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
by Camm, A John A John
Heart (British Cardiac Society), 2016-09-19, Vol.103 (4), p.307-314
14.
Rate control in atrial fibrillation
by Van Gelder, Isabelle C, Prof
The Lancet (British edition), 2016-08-20, Vol.388 (10046), p.818-828
15.
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
by Lip, Gregory Y H
Chest, 2018-11, Vol.154 (5), p.1121-1201
16.
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation
by Hernandez, Inmaculada
The American journal of cardiology, 2017-11-15, Vol.120 (10), p.1813-1819
17.
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial
by Vinereanu, Dragos
The Lancet (British edition), 2017-10-14, Vol.390 (10104), p.1737-1746
18.
Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
by Pokorney, Sean D., MD, MBA
The American heart journal, 2015, Vol.170 (1), p.141-148.e1
19.
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
by Holmes, David R, Prof
The Lancet (British edition), 2009, Vol.374 (9689), p.534-542
20.
Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort
by Alonso, Alvaro
Heart (British Cardiac Society), 2014-10, Vol.100 (19), p.1511-1516
